David Hurrell, MD
Cardiovascular Disease · Minneapolis, MNNPI 1194784835
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $204,800 of the $204,949 with a category attached, or 99.9%. Boston Scientific accounts for 99.9% of it on its own, with 4 other manufacturers making up the rest. Among cardiovascular disease clinicians in MN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 220 payments — averaging $931.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$205K
- Alnylam Pharmaceuticals Inc.$73
- AstraZeneca$30
- Akcea Therapeutics, Inc.$27
- Abbott$19
What the payments were for
- Consulting fees$204,800100%
- Food & beverage$1490%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 216 | $204,800 |
| Alnylam Pharmaceuticals Inc. | 1 | $73 |
| AstraZeneca | 1 | $30 |
| Akcea Therapeutics, Inc. | 1 | $27 |
| Abbott | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CLINICAL TRIAL PRODUCT$167,275
- ELUVIA$6,550
- GENERAL - STENTS$2,513
How this compares
$204,949 in reported general payments places this provider in the 95th percentile of 451 cardiovascular disease providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 363 | $465,576 |
| XareltoRivaroxaban | 126 | $139,731 |
| EntrestoSacubitril/Valsartan | 68 | $86,442 |
| JardianceEmpagliflozin | 44 | $50,053 |
| Repatha SureclickEvolocumab | 13 | $14,677 |
| Rosuvastatin Calcium | 446 | $7,701 |
| Valsartan | 147 | $5,857 |
| Ezetimibe | 208 | $5,746 |
| Metoprolol Succinate | 310 | $5,075 |
| Atorvastatin Calcium | 260 | $3,515 |
| Bumetanide | 33 | $2,997 |
| Carvedilol | 218 | $2,122 |
| Lisinopril | 173 | $2,063 |
| Losartan Potassium | 170 | $1,918 |
| Amlodipine Besylate | 199 | $1,566 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Minneapolis
- Jeffrey ChambersMinneapolis$3.2M
- Markus MeyerMinneapolis$786K
- Robert SchwartzMinneapolis$502K
- Robert VantasselMinneapolis$493K
- Nedaa SkeikMinneapolis$453K
- Joao CavalcanteMinneapolis$384K
- Inderjit AnandMinneapolis$384K
- Yader Sandoval PichardoMinneapolis$157K
- Charles HerzogMinneapolis$157K
- Tamas AlexyMinneapolis$117K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.